Photocure Partner Asieris to present First-ever Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 EUROGIN
Read Asieris' full media release here: https://asieris.com/asieris-to-unveil-first-ever-results-of-the-internat...
- Read Asieris' full media release here: https://asieris.com/asieris-to-unveil-first-ever-results-of-the-internat...
Cevira is a breakthrough photodynamic drug-device combination product that is being developed for non-surgical treatment of high-grade precancerous lesions of the cervix. - Photocure developed Cevira through Phase 1 and Phase 2 trials, and the global rights for development and commercialization were out-licensed to Asieris Meditech Co., Ltd in 2019.
- Asieris is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases.
- All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.